Author Interviews, COVID -19 Coronavirus, NEJM, Vaccine Studies / 13.12.2021
COVID-19: Pfizer Booster Dramatically Reduces Serious Infections in Israeli Study
MedicalResearch.com Interview with:
[caption id="attachment_58519" align="alignleft" width="150"]
Dr. Arbel[/caption]
Ronen Arbel, PhD
Outcomes Research, Community Medical Services Division
Clalit Health Service
Tel Aviv, Israel
Director, Maximizing Health Outcomes Research Lab
Sapir College, Sderot, Israel.
MedicalResearch.com: What is the background for this study?
Response: The emergence of the SARS-CoV-2 delta variant and reduced effectiveness over time of the BNT162b2 vaccine (Pfizer-BioNTech) led to a recent Coronavirus 2019 disease (Covid-19) resurgence in early vaccinated populations.
The Israeli Ministry of Health was the first in the world to approve a third (booster) dose of BNT162b2 to cope with this resurgence.
Dr. Arbel[/caption]
Ronen Arbel, PhD
Outcomes Research, Community Medical Services Division
Clalit Health Service
Tel Aviv, Israel
Director, Maximizing Health Outcomes Research Lab
Sapir College, Sderot, Israel.
MedicalResearch.com: What is the background for this study?
Response: The emergence of the SARS-CoV-2 delta variant and reduced effectiveness over time of the BNT162b2 vaccine (Pfizer-BioNTech) led to a recent Coronavirus 2019 disease (Covid-19) resurgence in early vaccinated populations.
The Israeli Ministry of Health was the first in the world to approve a third (booster) dose of BNT162b2 to cope with this resurgence.
